KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Depreciation & Amortization (CF) (2016 - 2025)

Eli Lilly (LLY) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $585.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 20.71% year-over-year to $585.7 million, compared with a TTM value of $2.0 billion through Dec 2025, up 13.02%, and an annual FY2025 reading of $2.0 billion, up 13.02% over the prior year.
  • Depreciation & Amortization (CF) was $585.7 million for Q4 2025 at Eli Lilly, up from $470.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $585.7 million in Q4 2025 and bottomed at $348.9 million in Q2 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $418.1 million, with a median of $405.8 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) increased 28.03% in 2021, then decreased 16.85% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $445.7 million in 2021, then decreased by 15.86% to $375.0 million in 2022, then grew by 3.31% to $387.4 million in 2023, then rose by 25.25% to $485.2 million in 2024, then grew by 20.71% to $585.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for LLY at $585.7 million in Q4 2025, $470.0 million in Q3 2025, and $478.5 million in Q2 2025.